Postherpetic neuralgia: A review

Internet Journal of Pain, Symptom Control and Palliative Care

Volumn 8, Issue 1, 2010, Pages

  Jericho, Barbara G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

And treatment; Clinical presentation; Epidemiology; Postherpetic neuralgia: pathophysiology; Prevention

Indexed keywords

EID: 77957748708     PISSN: 15288277     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Opstelten W, van Wijck AJ, Stolker RJ: Interventions to prevent postherpetic neuralgia: cutaneous and percutaneous techniques. Pain 2004;107:202-06.
2. Watson CPN, Deck JH, Morsehead C, Van der Kooy D, Evans RJ. Postherpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991;44:105-117.
3. Head H., Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900;23:353-523.
4. Noordenbos W. Pain: problems pertaining to the transmission of nerve impulses which gave rise to pain. Amsterdam: Elsevier, 1959:4-10,68-80.
5. Rowbotham MC, Baron R, Petersen KL, Fields HL. Spectrum of pain mechanisms contributing to postherpetic neuralgia. In: Watson CPN, Gershon AA, Editors. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier Press, 2001:183-95.
6. Loeser, JD. Herpes Zoster and Postherpetic Neuralgia. In The Management of Pain. Bonica, JJ (editor). Second Edition. Pennsylvania: Lea & Febiger, 1990: 257-63.
7. Yawn BP, Saddier P, Wollan P, St. Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9.
8. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67:241-51.
9. Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN, Gershon AA, eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press; 2001:39-64.
10. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326:748-750.
11. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 2005;352:2271-84.
12. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342-8.
13. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. The Clinical Journal of Pain 2002;18:350-54.
14. Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998;16:1768-70.
15. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22:341-7.
16. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
17. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;(9):863-9.
18. Tyring SK. Efficacy of famciclovir in the treatment of herpes zoster. Semin Dermatol 1996;15:27-31.
19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L, the Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842.
20. Rice ASC, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
21. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104.
22. Bennett MI, Simpson KH. Gabapentin in the treatment of neuropathic pain. Palliat Med 2004;18:5-11.
23. Hayashida K, Obata H, Nakajima K, Eisenach JC. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology 2008;109:1077-84.
24. Dworkin RH, Corbin AE, Young Jr. JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
25. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, muticentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-263.
26. Stacey BR, Barrett JA, Whalen E, Phillips,KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. The Journal of Pain 2008;9:1006-17.
27. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M, The 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 2004;109:26-35.
28. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810:93-99.
29. Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin. J Pain 2005;6:S29. Abstract 684.
30. Gore M, Sadosky A, Tai K, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Therapeutics 2007;29:1655-70.
31. Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. The Journal of Pain 2005;6:741-46.
32. Graff-Radford SB, Shaw L, Naliboff BN. Amitriptyline and Fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000;16:188-92.
33. Baldessarini RJ: Drug therapy of depression and anxiety disorders". Brunton LL, Lazo JS, Parker KL (eds): In: Goodman & Gilman's The Pharmacologic Basis of Therapeutics, 11th edition. McGraw-Hill, New York, USA, 2006, 429-460.
34. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br. J. Pharmacol 1988;95:95-102.
35. Ishii Y, Sumi T. Amitriptyline inhibits striatal efflux of neurotransmitters via blockade of voltage-dependent Na+ channels. Eur J Pharmacol 1992;221:377-380.
36. Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neuroscience Letters 1996;220:117-120.
37. Lavoie PA, Beauchamp G, Elie R. Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na(+)-Ca2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol 1990;68:1414-1418.
38. Ho K-Y, Huh BK, White WD, Yeh C-C, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. The Clinical Journal of Pain 2008;24:51-55.
39. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997;13:327-31.
40. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937-947.
41. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245-9.
42. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, Bogousslavsky J, Baron R. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8.
43. White RE, Hawkins K. A comparative cost analysis on the use of lidocaine patch 5% and branded and generic gabapentin for treatment of chronic neuropathic and non-neuropathic pain conditions. Arthritis Rheum 2005;52:S527.
44. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989;21:265-270.
45. Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993;15:510-526.
46. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-1028.
47. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
48. Fan BF. Postmarketing Surveillance Study of Oxycontin ® tablets for relieving moderate to severe postherpetic neuralgia pain. Oncology 2008;74:66-71.
49. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants inpostherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
50. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;1223-1232.
51. Tassain V, Attal N, Fletcher D, Brasseur L, Dégieux P, Chauvin M, Bouhassira D. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003;104:389-400.
52. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003;104:323-331.
53. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000;87:121-129.
54. Dworkin RH, Johnson RW. A belt of roses from hell: pain in herpes zoster and postherpetic neuralgia. In: Block AR, Kremer EF, Fernandez E, editors. Handbook of pain syndromes: biopsychosocial perspectives, Hillsdale, NJ:Erlbaum, 1999. 371-402.
55. Rowbotham MC, Taylor K. Herpes zoster and postherpetic neuralgia. In: Yaksh TL, Lynch C, Zapol WM, Maze M, Biebuyck JF, Saidman LJ, Editors. Anesthesia:biologic foundations, Philadelphia: Lippincott-Raven Publishers, 1998. 879-888.
56. Kikuchi A, Kotani N, Sato T, Takamura K, Sakai I, Matsuki A. Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Regional Anesthesia and Pain Medicine 1999;24:287-293.
57. Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M, Asai M, Matsuki A. Intrathecal methylprednisolone for intractable postherpetic neuralgia. The New England Journal of Medicine 2000;343:1514-19.
58. Nelson DA. Intraspinal therapy using methylprednisolone acetate: Twenty-three years of clinical controversy. Spine 1993;18:278-86.
59. Wilkinson HA. Intrathecal Depo-Medrol: A literature review. Clin J Pain 1992;8:49-56.
60. Krames E. Implantable devices for pain control: spinal cord stimulation and intrathecal therapies. Best Pract Res Clin Anaesthesiol 2002;16:619-649.
61. Harke H, Gretenkort P, Ladleif HU, Koester P, Rahman S. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth Analg 2002;94:694-700.